SMMT News

Summit is teaming up with AstraZeneca and Daiichi to test ivonescimab with Datroway across breast and lung cancers, broadening its potential.

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZenecas (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity investment will support continued acceleration of the development of ivonescimab, a novel, potential first-in-class investigational...

Biotech companies this week spent on experimental therapies, including autoimmune drugs, next-generation obesity pills and cancer combinations.

AstraZeneca & Daiichi Sankyo team up with Summit Therapeutics to test Datroway + ivonescimab combo in triple-negative breast cancer.read more...

The firms will begin their collaboration with a Phase 3 study of Ivonescimab in combination with Datroway in first-line triple-negative breast cancer

(RTTNews) - Daiichi Sankyo (4568.TS) and AstraZenca (AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics (SMMT) to evaluate Datroway (datopotamab deruxtecan) in combination with ivonescimab across multiple solid tumors, including lung and brea...

Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) to evaluate ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in combination with...

SMMT shares jump as AstraZeneca commits $2 billion to accelerate ivonescimab development and expand clinical collaboration.

The biotechnology sector is entering a catalyst-heavy stretch, with Iovance Biotherapeutics (NASDAQ:IOVA), NeOnc Technologies Holdings (NASDAQ:NTHI), and Summit Therapeutics (NASDAQ:SMMT) approaching potentially significant commercial, clinical, and regulatory milestones.